Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT04369534
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT04369534
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Croatia
- Registry status
- Completed
Technical summary
Registry record NCT04369534. Randomized; no masking; primary purpose treatment. Start 2015-12-01 (actual); primary completion 2019-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
- Acronym
- SPARELIFE
- Condition
- Acute Coronary Syndrome
- Condition
- STEMI
- Condition
- NSTEMI - Non-ST Segment Elevation MI
- Condition
- PLATELET AGGREGATION
- Condition
- INDIVIDUALIZED THERAPY
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- Ticagrelor
- Lead sponsor
- University of Zagreb
- Collaborator
- Croatian Science Foundation
- Collaborator
- Clinical Hospital Centre Zagreb
Record details
- Record id
cardio:ct-nct04369534- Content hash
a950f7ac84735311e4ee6c4337111df27326d836113df40d98b483d1745edbf3